US76243J1051 - Common Stock
RHYTHM PHARMACEUTICALS INC
NASDAQ:RYTM (5/8/2024, 7:17:17 PM)
After market: 38 -0.92 (-2.36%)38.92
-0.43 (-1.09%)
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The company is headquartered in Boston, Massachusetts and currently employs 177 full-time employees. The company went IPO on 2017-10-05. The firm is focused on advancing its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). The company is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.
RHYTHM PHARMACEUTICALS INC
222 Berkeley Street, 12th Floor Boston
Boston MASSACHUSETTS 02116
P: 18572644280
CEO: David P. Meeker
Employees: 177
Website: http://www.rhythmtx.com
Although it’s typically the season for selling, shifting market conditions call for the best Nasdaq stocks to buy in May.
RYTM stock results show that Rhythm Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat...
Here you can normally see the latest stock twits on RYTM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: